StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
PAVS

Paranovus Entertainment Technology Ltd.

PAVS Nasdaq Services-Computer Processing & Data Preparation EDGAR ↗
$3.99
-0.39 -8.90%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$314K
Revenue (TTM) ⓘ
$14.6M
Net income (TTM) ⓘ
-$12.7M
EPS (TTM) ⓘ
$-8,485.00
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
$10.3M
Total assets ⓘ
$36.9M
Gross margin ⓘ
16.5%
52-week range ⓘ
$3.76 – $148,800.00

AI briefing

from the latest 10-K, 10-Q and 8-K events

Paranovus Entertainment Technology Ltd. is a Cayman Islands holding company listed on Nasdaq that shifted from a nutraceutical business to entertainment and related technology operations, reporting $14.6M revenue in fiscal 2026.

What they do

Paranovus operates through subsidiaries in the US, Hong Kong and the PRC, including 2lab3 Inc. and Paranovus Entertainment Technology Limited. The filings describe a corporate structure with former nutraceutical entities such as Fujian Happiness and newer entertainment technology operations. The company generates revenue from entertainment technology services, though the filing excerpts do not break out individual product lines.

Revenue drivers

  • Entertainment technology operations — The company reported $14.6M in annual revenue for fiscal 2026, with no single product breakdown provided in the excerpts.
  • Subsidiary 2lab3 Inc. — A wholly owned Delaware corporation; the filings do not disclose its specific revenue contribution.
  • PRC subsidiaries — Paranovus PRC and related entities operate in China; their revenue contribution is not separately quantified in the excerpts.

Recent performance

Fiscal 2026 revenue was $14.6M, up from $71,542 in fiscal 2025. Net loss was $12.7M in fiscal 2026, compared with a $7.9M loss in fiscal 2025. Operating cash flow was negative $1.4M in fiscal 2026, improving from negative $2.7M in fiscal 2025. As of March 31, 2026, total assets were $36.9M, total liabilities $3.9M, and shareholder equity $31.2M.

Strategy

The company has transitioned from its former nutraceutical operations toward entertainment technology. It maintains subsidiaries in the US, Hong Kong and the PRC. No specific investment targets or growth initiatives are detailed in the available excerpts. The company completed a 1-for-12 reverse split effective March 31, 2026, and a 1-for-100 reverse split effective June 29, 2026.

Risks

  • History of losses — The company reported net losses of $12.7M in fiscal 2026, $7.9M in fiscal 2025, $10.1M in fiscal 2024, and larger losses in prior years.
  • Revenue concentration — Revenue is not broken out by segment in the excerpts, making it difficult to assess dependence on any single source.
  • Reverse stock splits — Two reverse splits in 2026 (1-for-12 and 1-for-100) indicate prior low share price levels.
  • Negative operating cash flow — Operating cash flow has been negative for each year shown, including negative $1.4M in fiscal 2026.

Outlook

The filing excerpts do not include specific forward guidance. Management's discussion and analysis and strategy statements were not fully captured in the available text. No revenue or earnings projections are provided in the excerpts.